Evogene (EVGN) has released an update.
Evogene Ltd. has released its unaudited interim consolidated financial statements, revealing a decrease in cash and cash equivalents from $20,772 thousand on December 31, 2023, to $9,484 thousand by June 30, 2024. The company’s total current assets diminished from $34,469 thousand to $25,774 thousand in the same period, while overall liabilities and shareholders’ equity also saw a decline.
For further insights into EVGN stock, check out TipRanks’ Stock Analysis page.
